Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834165 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
A Phase 4 study of Allergic Reactions, sponsored by ARS Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 2
- Study locations
NCT06834165: Recruiting Phase 4 study of Allergic Reactions, sponsored by ARS Pharmaceuticals.
NCT06834165 is a Phase 4 study of Allergic Reactions that is actively recruiting participants, run by ARS Pharmaceuticals. The registered enrollment target is 600 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (16% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06834165, a Phase 4 study of Allergic Reactions, is actively recruiting participants, sponsored by ARS Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
Conditions Studied
Interventions
- DRUG Neffy
- DRUG Adrenaline
Study Locations (2)
California
- Orso Health, Inc. - La Jolla
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What NCT06834165 shows while recruiting
NCT06834165 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Allergic Reactions appearing as the primary indexed condition, and to 2 interventions - of which Neffy is the first listed.
NCT06834165 reports a single indexed study location in California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06834165 about?
NCT06834165 is a clinical study titled "Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy". The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
What is the current status of trial NCT06834165?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2025-05-20. Estimated completion is 2026-06.
What conditions does trial NCT06834165 study?
This clinical trial studies the following conditions: Allergic Reactions.
What interventions are being tested in trial NCT06834165?
The interventions under investigation include: Neffy (DRUG), Adrenaline (DRUG).
Who is sponsoring clinical trial NCT06834165?
This trial is sponsored by ARS Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06834165 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Reactions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06834165's enrollment target sits among peer trials
600 137th of 2000 higher than 1,855 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI